Prevalence of Comorbidities and Their Impact on One-year Outcomes in Iranian Patients Hospitalized with ST-segment Elevation Myocardial Infarction

Document Type : Original Article

Authors

Behavioral Disease Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Abstract

Introduction:  Introduction: While it is well-known that comorbidities like hypertension are associated with an increased risk for cardiovascular diseases (CVDs), the risk for death and subsequent CV complications has not been adequately addressed. Therefore, this study was aimed to examine the association between comorbidities and one-year outcomes in patients with STEMI.
Methods: This hospital-based study was a part of the Kermanshah STEMI Registry. After applying inclusion criteria, a total of 2,443 patients were assessed. The data were collected using a standardized case report developed by the European Observational Registry Program (EORP). The outcomes including vital status and major adverse cardiovascular events (MACE) were assessed. We assessed the independent predictors of death and MACE using multivariable logistic regression models.
Results: At first-year follow-up, out of the 2443 patients, 268 (11.06) patients died and 403 (19.0) patients experienced the MACE. On multivariate analysis, patients with hypertension (OR 1.69; 95% CI 1.19-2.38) and diabetes (OR 1.61; 95% CI 1.10-2.34) had a higher risk for death. Patients with hyperlipidemia were at the lowest risk of death (OR 0.63; 95% CI 0.41-0.97).
Conclusion: Diabetes mellitus and hypertension increased the risk of death, however, hyperlipidemia decreased the risk of death. The clinical implications highlight the need for tailoring intervention in all aspects of secondary prevention of CVD especially in patients suffering from comorbidities, managing the common comorbidities, and monitoring diabetics and hypertensive patients.

Keywords

References

  1. International Monetary Fund. Asia, Pacific Dept. Regional Economic Outlook, April 2012, Asia and Pacific: Managing Spillovers and Advancing Economic Rebalancing. International Monetary Fund; 2012 Apr 27.
  2.  Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. circulation. 2015 Jan 27;131(4):e29-322.
  3.  Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A, et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation. 2014 Apr 8;129(14):1493-501.
  4. Wallentin L, Kristensen SD, Anderson JL, Tubaro M, Sendon JL, Granger CB, et al. How can we optimize the processes of care for acute coronary syndromes to improve outcomes?. American heart journal. 2014 Nov 1;168(5):622-31.
  5.  Campo G, Saia F, Guastaroba P, Marchesini J, Varani E, Manari A, et al. Prognostic impact of hospital readmissions after primary percutaneous coronary intervention. Archives of internal medicine. 2011 Nov 28;171(21):1948-9.
  6. Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. The lancet Diabetes & endocrinology. 2017 Dec 1;5(12):941-50..
  7. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. circulation. 2017 Mar 7;135(10):e146-603.
  8. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. European heart journal. 2015 May 14;36(19):1163-70.
  9. Hess CN, Clare RM, Neely ML, Tricoci P, Mahaffey KW, James SK, et al. Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. American heart journal. 2017 May 1;187:194-203.
  10. Preis SR, Hwang SJ, Coady S, Pencina MJ, D'Agostino Sr RB, Savage PJ, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009 Apr 7;119(13):1728-35.
  11. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011 Feb;42(2):517-84.
  12. Li S, Peng Y, Wang X, Qian Y, Xiang P, Wade SW, et al. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clinical cardiology. 2019 Mar;42(3):391-9.
  13. Rapsomaniki E, Thuresson M, Yang E, Blin P, Hunt P, Chung SC, et al. Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. European Heart Journal–Quality of Care and Clinical Outcomes. 2016 Jul 1;2(3):172-83.
  14.  Siabani H, Davidson P, Siabani S, Gholizadeh L, Karim H, Najafi F, et al. The Kermanshah acute coronary syndrome registry: Rational and design. Acta Scientific Medical Sciences. 2019 Jul 16.
  15. Thygesen K, Alpert JS, Jaffe AS. Erratum: Third universal definition of myocardial infarction (Journal of the American College of Cardiology (2012) 60 (158-98. Journal of the American College of Cardiology. 2013 Feb 5;61(5):598.
  16. Tajik AA, Dobre D, Aguilar D, Kjekshus J, Zannad F, Dickstein K, et al. A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High‐Risk MI Database. European Journal of Heart Failure. 2017 May;19(5):635-42.
  17.  Nguyen HL, Nguyen QN, Ha DA, Phan DT, Nguyen NH, Goldberg RJ. Prevalence of comorbidities and their impact on hospital management and short-term outcomes in Vietnamese patients hospitalized with a first acute myocardial infarction. PloS one. 2014 Oct 3;9(10):e108998.
  18.  Van Der Heijden AA, van’t Riet E, Bot SD, Cannegieter SC, Stehouwer CD, Baan CA, et al. Risk of a recurrent cardiovascular event in individuals with type 2 diabetes or intermediate hyperglycemia: the Hoorn Study. Diabetes care. 2013 Nov 1;36(11):3498-502.
  19.  Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC cardiovascular disorders. 2017 Dec;17:1-8.
  20. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, et al. Diabetes and mortality following acute coronary syndromes. Jama. 2007 Aug 15;298(7):765-75.
  21.  Mehlum MH, Liestøl K, Kjeldsen SE, Julius S, Hua TA, Rothwell PM, et al. Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. European heart journal. 2018 Jun 21;39(24):2243-51.
Journal of Cardio-Thoracic Medicine
Volume 12, Issue 3
September 2024
Pages 1381-1387

Files

Share

How to cite

Statistics